iBio, Inc.

IBIO

US4510337086

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:00:00 2024-07-03 pm EDT			5-day change	1st Jan Change
1.97 ^USD	+1.03%		-6.19%	+43.80%

Jun. 03	Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. for $8.5 million.	CI
May. 28	Chardan Research Starts iBio With Buy Rating, $5 Price Target	MT

Ibio, Inc. Appoints Dr. Martin Brenner, to the Board of Directors, Effective June 1, 2024

May 13, 2024 at 04:08 pm EDT

Ibio, Inc. Appointed CEO and Chief Scientific Officer, Dr. Martin Brenner, to the Board of Directors, effective June 1, 2024.

Latest news about iBio, Inc.

Texas A&M University System Board of Regents acquired Manufacturing facility located in Bryan, Texas of iBio, Inc. for $8.5 million.	Jun. 02	CI
Chardan Research Starts iBio With Buy Rating, $5 Price Target	May. 28	MT
IBio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024	May. 13	CI
Ibio, Inc. Appoints Dr. Martin Brenner, to the Board of Directors, Effective June 1, 2024	May. 13	CI
IBio, Inc. announced that it has received $15.066157 million in funding from ADAR1 Capital Management, LLC, Lynx1 Capital Management LP, Ikarian Capital, LLC and other investors	Mar. 31	CI
Top Premarket Gainers	Mar. 28	MT
Top Midday Gainers	Mar. 27	MT
Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	Mar. 27	MT
Transcript : IBio, Inc. - Special Call	Mar. 27
US Futures Trend Higher Wednesday Pre-Bell as Investors Eye Impending Economic, Inflation Data Readings	Mar. 27	MT
Top Premarket Gainers	Mar. 27	MT
IBio, Inc. and AstralBio, Inc. Announce Transformative AI Drug Discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases	Mar. 27	CI
IBio, Inc. announced that it has received $14 million in funding	Mar. 25	CI
IBio Sells Preclinical PD-1 Antagonist Antibody Program to Otsuka	Feb. 26	DJ
Otsuka Pharmaceutical Co., Ltd. completed the acquisition of Preclinical PD-1 Agonist Antibody Program of iBio, Inc..	Feb. 24	CI
IBio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 09	CI
Top Midday Decliners	Dec. 05	MT
Top Premarket Decliners	Dec. 05	MT
North American Morning Briefing : November Rally Pauses Ahead of This Week's PCE Report	Nov. 28	DJ
IBio Board Approves 20-to-1 Reverse Split of Common Stock Effective Nov. 29; Shares Sink 11% After Hours	Nov. 27	MT
IBio, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 14	CI
IBio, Inc. Announces Expansion of its AI-Powered Technology Stack with Launch of ShieldTx	Nov. 01	CI
North American Morning Briefing : Stock Futures, -2-	23-10-02	DJ
IBio, Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-09-27	CI
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ

iBio, Inc. is a preclinical stage biotechnology company that leverages artificial intelligence (AI) for the development of precision antibodies. The Company develops biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard-to-target cancers and other diseases. Its StableHu technology is an AI-based tool designed to predict a library of antibodies with fully human Complementarity-Determining Region (CDR) variants based on an input antibody. It is in the process of building its preclinical pipeline, which focuses primarily on immuno-oncology. Its pipeline includes IBIO-101, Endostatin E4, TROP-2 x CD3, MUC16, EGFRvIII, and CCR8. IBIO-101 is an anti-CD25 monoclonal antibody (mAb) that has demonstrated in preclinical models of disease the ability to bind and deplete immunosuppressive regulatory T (Treg) cells to inhibit the growth of solid tumors.

Sector

Pharmaceuticals

Calendar

2024-09-23 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.97 USD

Average target price

5 USD

Spread / Average Target

+153.81%

Consensus

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IBIO, INC.	+43.80%	16.99M
ELI LILLY AND COMPANY	+54.07%	809B
NOVO NORDISK A/S	+39.38%	624B
JOHNSON & JOHNSON	-7.05%	351B
MERCK & CO., INC.	+15.44%	319B
ABBVIE INC.	+5.72%	289B
ASTRAZENECA PLC	+14.77%	240B
ROCHE HOLDING AG	+0.57%	219B
NOVARTIS AG	+14.80%	220B
AMGEN INC.	+7.42%	166B

Other Pharmaceuticals

iBio, Inc.

Equities

IBIO

US4510337086

Pharmaceuticals

Ibio, Inc. Appoints Dr. Martin Brenner, to the Board of Directors, Effective June 1, 2024

Latest news about iBio, Inc.

Chart iBio, Inc.

Company Profile

Income Statement Evolution

Analysts' Consensus

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals